分组1 - BankUnited, Inc. reported quarterly earnings of $0.91 per share, exceeding the Zacks Consensus Estimate of $0.79 per share, and up from $0.72 per share a year ago, representing an earnings surprise of +15.19% [1] - The company posted revenues of $273.93 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.12%, compared to year-ago revenues of $250.21 million [2] - BankUnited has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates two times in the same period [2] 分组2 - The stock has added about 1.4% since the beginning of the year, underperforming the S&P 500's gain of 7.3% [3] - The current consensus EPS estimate for the coming quarter is $0.81 on revenues of $273.49 million, and for the current fiscal year, it is $3.20 on revenues of $1.07 billion [7] - The Zacks Industry Rank for Banks - Major Regional is currently in the top 11% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Insights - Akari Therapeutics is advancing its research on PH1, a novel spliceosome modulator that induces cancer cell death and activates the immune system to combat cancer [1][4] - The company is focused on developing antibody drug conjugates (ADCs) utilizing the PH1 payload, with ongoing preclinical studies expected to yield new data by year-end [1][3] Company Overview - Akari Therapeutics specializes in oncology biotechnology, developing innovative ADCs with a unique mechanism of action through the PH1 payload, which disrupts RNA splicing [4] - The lead candidate, AKTX-101, targets the Trop2 receptor and has shown significant activity and prolonged survival in preclinical studies compared to traditional ADCs [4] Research and Development - Ongoing research aims to explore the effects of PH1 on key oncogenic drivers such as KRAS, BRAF, and FGFR3, with preliminary data anticipated soon [2][3] - The PH1 payload has demonstrated the ability to induce cytotoxicity in cancer cells and activate immune responses, potentially leading to improved therapeutic outcomes [2][6]

Core Insights - Clearmind Medicine Inc. has successfully completed site initiation at Tel Aviv Sourasky Medical Center for its Phase I/IIa clinical trial of CMND-100, targeting Alcohol Use Disorder (AUD) [1][2] - The trial is multinational and multi-center, assessing safety, tolerability, and pharmacokinetics of CMND-100, while also exploring early efficacy signals [2][3] - CMND-100 utilizes the molecule 5-methoxy-2-aminoindane (MEAI) and has shown promising preclinical results in reducing alcohol cravings, addressing a significant unmet need in AUD treatment [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents [5] Clinical Trial Details - The Phase I/IIa trial includes prestigious sites such as Yale School of Medicine and Johns Hopkins University, alongside TASMC and Hadassah-University Medical Center [2] - The trial is led by Prof. David Zeltser at TASMC, enhancing Clearmind's clinical network and patient enrollment [2][3]

Hemostemix Closes Sale of 23rd ACP-01 Therapy Convertible DebentureJuly 23, 2025 8:55 AM EDT | Source: Hemostemix Inc.Calgary, Alberta--(Newsfile Corp. - July 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely treated 498 patients for various forms of cardiovascular disease, including peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, isc ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

I have been working in the logistics sector for almost two decades. I have been into stock investing and macroeconomic analysis for almost a decade. Currently, I focus on ASEAN and NYSE/NASDAQ Stocks, particularly in banks, telco, logistics, and hotels. Since 2014, I have been trading on the PH stock market. I focus on banking, telco, and retail sectors. A colleague encouraged me to engage in the stock market as part of my portfolio diversification instead of putting all my savings in banks and properties. ...

Léonne is the first framework to unify trust modeling, network analysis, and quantum-resistant cryptography into a single, modular, and production-ready system. Léonne facilitates the scalability, security, and decentralization trade-offs inherent in existing models like Proof-of-Work and Proof-of-Stake. Introduces a trust-based, topologically structured consensus model, leveraging advanced mathematics and quantum technologies to enable efficient, secure, and decentralized network partitioning at scale. De ...

Key Highlights Strategic Capitalization: Matador has executed a Purchase Agreement for a USD $100 million secured convertible note facility (the “Facility”) with ATW Partners, featuring an initial USD $10.5 million tranche. Exclusive Use of Proceeds: Proceeds are earmarked for purchasing Bitcoin as part of Matador’s treasury allocation strategy, with the intention of increasing long-term Bitcoin-per-share (BPS).Institutional Partnership: ATW Partners—an institutional investor known for structuring growth-st ...

Key Highlights Strategic Capitalization: Matador has executed a Purchase Agreement for a USD $100 million secured convertible note facility (the “Facility”) with ATW Partners, featuring an initial USD $10.5 million tranche. Exclusive Use of Proceeds: Proceeds are earmarked for purchasing Bitcoin as part of Matador’s treasury allocation strategy, with the intention of increasing long-term Bitcoin-per-share (BPS).Institutional Partnership: ATW Partners—an institutional investor known for structuring growth-st ...

PayPal has launched a cross-border payments platform connecting many of the world’s largest payments networks.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.PayPal World, announced Wednesday (July 23), is debuting ...